HyperSinc

Qihan Biotech

Co-founded in 2017 by two pioneers in genome editing technology, Qihan Biotech has world-leading capabilities in multiplexable genome editing as well as vast experience in Immune shielding. We apply these tools in both human stem cells and animal germline cells to deliver novel immune-privileged cel

Total raised
—
Last round
—
Headcount
Pro
Δ heads 90d
Pro
Web traffic 90d
Pro
Why it's on the radar
TeamFundraising signals (who's likely raising, and why) are on Team.Start a free 14-day trial →
Funding history · 0 rounds

No rounds on record yet.

Key people
ProKey people, exec moves and open roles are on Pro.Start a free 14-day trial →